Literature DB >> 24329556

Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation.

L Lindell-Osuagwu1, M Hakkarainen, K Sepponen, K Vainio, T Naaranlahti, H Kokki.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The European Paediatric Regulation aims to reduce off-label use of medicines in paediatric pharmacotherapy. Prescribing for off-label use and unauthorized medicines was common in the paediatric wards of the Kuopio University Hospital in 2001. To evaluate the possible impact of the Regulation on the prevalence and the frequency on such prescribing, we repeated the study in 2011 as it was conducted 10 years earlier.
METHODS: In this prospective study, the prescriptions for patients below 18 years of age were reviewed during a 2-week period in each of the three wards; neonatal intensive care unit, general paediatric ward and paediatric surgical ward in April and May 2011. The medicine's authorizing status of all prescriptions was determined according to the approved summary of product characteristics valid during the study in Finland. Data concerning unauthorized medicines were also recorded and classified.
RESULTS: Out of the entire study population of 123 patients, 119 received a total of 1054 prescriptions in 2011. The proportion of patients with at least one prescription for off-label use or for an unauthorized medicine was significantly higher, 79% (n = 97) in 2011, compared to 58% in 2001 (P < 0·001). For newborns, significantly more prescriptions were for off-label use in 2011 than in 2001 (51% vs. 22%; P < 0·001). The proportion of prescriptions for unauthorized medicines was significantly higher in children below 2 years of age than in older children in both years (21% vs. 5% in 2011 and 24% vs. 3% in 2001, P < 0·001). WHAT IS NEW AND
CONCLUSION: The prescribing for off-label use and unauthorized medicines was more prevalent in 2011 than in 2001. This indicates that the recent legislation has had only minor or no impact on the authorizing status of medicines commonly used in paediatric inpatients in specialized care.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  hospitals; off-label; paediatric; paediatrics; pharmaceutical preparations; prescriptions; unauthorized; unlicensed

Mesh:

Year:  2013        PMID: 24329556     DOI: 10.1111/jcpt.12119

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  20 in total

1.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

Review 2.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

3.  Unlicensed and off-label use of drugs in pediatric surgical units at tertiary care hospitals of Pakistan.

Authors:  Muhammad Aamir; Jamshaid Ali Khan; Faisal Shakeel; Syed Muhammad Asim
Journal:  Int J Clin Pharm       Date:  2017-06-09

Review 4.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

5.  Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.

Authors:  Pyry Välitalo; Merja Kokki; Veli-Pekka Ranta; Klaus T Olkkola; Andrew C Hooker; Hannu Kokki
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

6.  Off-Label Drug Use in Pediatric Out-Patient Care: A Multi-Center Observational Study.

Authors:  Aeshah AlAzmi; Zahra Alasmari; Consuela Yousef; Ahmed Alenazi; Mohammed AlOtaibi; Hani AlSaedi; Adnan AlShaikh; Amani AlObathani; Omaima Ahmed; Loie Goronfolah; Mousa Alahmari
Journal:  Hosp Pharm       Date:  2020-08-31

7.  New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products.

Authors:  Ann-Katrine Birkelund Mogensen; Helle Christiansen; Marie Louise De Bruin; Christine Erikstrup Hallgreen
Journal:  Paediatr Drugs       Date:  2022-08-13       Impact factor: 3.930

8.  Exploratory Findings of Prescribing Unlicensed and Off-Label Medicines Among Children and Neonates.

Authors:  Sadia Shakeel; Wajiha Iffat; Shagufta Nesar; Hina Zaidi; Shazia Jamshed
Journal:  Integr Pharm Res Pract       Date:  2020-02-05

Review 9.  Extent, reasons and consequences of off-labeled and unlicensed drug prescription in hospitalized children: a narrative review.

Authors:  Wasim Shuib; Xin-Yin Wu; Fang Xiao
Journal:  World J Pediatr       Date:  2021-06-02       Impact factor: 2.764

10.  Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature.

Authors:  H Christine Allen; M Connor Garbe; Julie Lees; Naila Aziz; Hala Chaaban; Jamie L Miller; Peter Johnson; Stephanie DeLeon
Journal:  J Okla State Med Assoc       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.